
Zomedica (ZOM) Earnings Dates & Reports
Zomedica (ZOM) Most Recent Earnings
Report DateMar 13, 2025
Period EndingQ4 2024
Est. EPS-$0.01
Actual EPS-$0.01
EarningsMeet
Zomedica (ZOM) Earnings
View the latest Zomedica (ZOM) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in Zomedica (ZOM)
Order type
Buy in
Order amount
Est. shares
0 shares
Zomedica (ZOM) Earnings per Share (EPS) History
Signup for full accessBrowse free
Zomedica (ZOM) Latest Earnings
The value each ZOM share was expected to gain vs. the value each share gained.
Zomedica (ZOM) reported its most recent earnings on Mar 13, 2025 for Q4 2024, posting earnings per share (EPS) of -$0.01. This exceeded analysts' expectations of -$0.01 by 0.00%, marking a Meet.
For comparison, Zomedica reported EPS of -$0.02 in the same quarter last year.
The company is expected to announce its next earnings report on 08/12/2025, with analysts projecting an EPS of $0.
Zomedica (ZOM) Earnings History
Zomedica (ZOM) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the Zomedica’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
Report date | Price 1D before | Price 1D after | Change |
---|---|---|---|
Mar 13, 2025 | — | — | — |
Nov 7, 2024 | — | — | — |
Aug 14, 2024 | — | — | — |
May 9, 2024 | — | — | — |
Zomedica (ZOM) Earnings FAQs
Zomedica (ZOM) last reported earnings on Mar 13, 2025 for Q4 2024, posting an EPS of -$0.01, which Meet the estimate of -$0.01 by 0.00%.
For Q4 2024, Zomedica (ZOM) reported an EPS of -$0.01, missing analysts' estimate of -$0.01 by 0.00%.
For Q4 2024, Zomedica (ZOM) Meet expectations with an actual EPS of -$0.01 vs. an estimated EPS of -$0.01.
Following the last earnings report on Mar 13, 2025, Zomedica (ZOM)'s stock price moved — from — to —.
The next Zomedica (ZOM) earnings call is scheduled for Aug. 12, 2025, where executives will discuss financial results and outlook.